Pico IV
Pico IV is a Sacramento-based private company that develops and sells the world's first sterile CBD IV solution, using patented pico-emulsion technology to make CBD water-soluble and filterable, sold to licensed clinics and IV therapy franchise networks through a HIPAA-compliant provider portal.
- Company typePrivate
- Founded2023
- HeadquartersSacramento, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Pico IV does
Pico IV, Inc. is a Sacramento, California-based privately held company founded in 2023 that develops and sells the world's first sterile CBD intravenous (IV) solution, protected by US Patent #12,569,504. Its core technology is a proprietary pico-emulsion process that reduces CBD particle size to the picometer scale (claimed to be 1,000x smaller than nanoemulsions), enabling CBD to become water-soluble and pass through sterile filtration, a previously unsolved constraint for IV-delivered cannabinoids. Products are manufactured in a cGMP facility using e-beam sterilization and are tested at ISO-accredited third-party labs (KCA Labs, California Ag Labs), with Certificates of Analysis published for each batch.
The product portfolio includes sterile CBD Broad Spectrum vials in 5ml, 10ml, 20ml, and 50ml formats and a Core-A formulation featuring acidic cannabinoids (CBD-A and CBG-A). The company serves licensed medical clinics, functional and regenerative medicine practices, and national IV therapy franchise networks (DRIPBaR with 120+ locations, iCRYO with 50 US/Canada locations, and Liquivida). Distribution runs through a HIPAA-compliant B2B provider portal (with training, ordering, and recurring 20%-discount subscriptions) and a small direct-to-consumer e-commerce channel; the website ships only within the United States. Revenue is generated via per-vial product sales and provider subscriptions, with per-unit pricing not publicly disclosed.
Operationally, Pico IV has built a footprint of 200+ clinics across nearly all 50 US states and has been expanding into clinical and specialty applications through collaborations such as a January 2026 neurologist-guided protocol with BrainThrive, PC. The company is founder-owned and operated, with no disclosed external venture funding, no parent company, and no subsidiaries. Its leadership engagement includes Liquivida founder Sam Tejada joining its Advisory Board as a spokesperson, and clinical data infrastructure is being built on AdvancedMD and REDcap Cloud integrations to document patient-reported outcomes.
Pico IV firmographics
Firmographics- Name
- Pico IV
- Legal name
- Pico IV Inc.
- Website
- https://picoiv.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Pico IV is a Sacramento-based private company that develops and sells the world's first sterile CBD IV solution, using patented pico-emulsion technology to make CBD water-soluble and filterable, sold to licensed clinics and IV therapy franchise networks through a HIPAA-compliant provider portal.
- Ownership category
- akta.pro rank
Pico IV industry classification
Industry- Product category
- Sterile CBD IV Pharmaceutical Products
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)
- akta.pro secondary industries
- Hemp & CBD Product Wholesale Distribution (CRAOAIAG), CBD/Hemp Wellness & Supplements Retail (CRANAHAC)
Keywords
Where Pico IV is headquartered
LocationHeadquarters
- HQ city
- Sacramento
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Pico IV business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Revenue model
- Sterile CBD IV Product Sales: Pico IV sells its sterile CBD solution vials directly to healthcare providers and clinics through a B2B provider portal and e-commerce platform. Providers purchase products for administration in clinical settings. The company offers subscribe-and-save options for recurring purchases.
- B2B Provider Portal: Healthcare providers register through a HIPAA-compliant provider portal to access products, training resources, ordering system, and clinical information. The portal facilitates efficient inventory management and reordering.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Monthly | Standard Retail Products |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Pico IV product offering
Product offeringCore offering
Pico IV develops, manufactures, and distributes the world's first sterile CBD IV solution using proprietary pico-emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and passage through sterile filtration for true IV-administerable CBD. The company sells sterile CBD Broad Spectrum Vials (in 5ml, 10ml, 20ml, and 50ml sizes) and a Core-A acidic cannabinoid formulation to licensed medical clinics, wellness franchises, and consumers through a HIPAA-compliant B2B Provider Portal and DTC e-commerce.
Product overview
Pico IV is a B2B wellness technology company that developed and manufactures the world's first sterile CBD IV solution, protected by US Patent #12,569,504. The company's core offering consists of proprietary pico emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and true sterile filtration for IV administration. The product portfolio includes CBD Broad Spectrum Vials (available in 5ml, 10ml, 20ml, and 50ml sizes with varying potencies) and Core-A formulations featuring acidic cannabinoids (CBD-A and CBG-A). All products undergo rigorous third-party testing at ISO-accredited labs (KCA Labs, California Ag Labs) with published Certificates of Analysis. The company operates exclusively through licensed medical clinics via a HIPAA-compliant Provider Portal that offers ordering systems, clinical training, and support resources. Pico IV's products are currently available in over 200 clinics across nearly all 50 US states.
Differentiator
Problem solved
Functional benefit
Products and services
- PICO IV Sterile CBD IV Solution World's first and only sterile CBD IV solution, utilizing proprietary pico-emulsion technology that reduces CBD particles to picometer scale for water solubility and sterile filtration, enabling direct IV administration of CBD for enhanced bioavailability. Sold to licensed medical clinics and wellness providers for in-clinic IV administration.
- PICO IV CBD Broad Spectrum Vial Sterile CBD IV solution available in 5ml, 10ml, 20ml, and 50ml vials with varying CBD concentrations (approximately 6.4 mg/mL potency). Contains multiple cannabinoids including CBD, CBG, CBGa, CBDa, CBC, and CBN. Third-party lab tested for pesticides, microbials, mycotoxins, heavy metals, and residual solvents.
- PICO IV Core-A Specialized CBD IV formulation featuring CBD-A and CBG-A acidic cannabinoids at 0.161 mg/mL potency in 5.8ml vials. Third-party lab tested for purity and potency.
- PICO IV Provider Portal HIPAA-compliant B2B platform providing licensed medical clinics access to ordering, inventory management, clinical resources, training materials, and Certificate of Analysis documentation. Includes 1-on-1 training, FAQs, forum groups, and downloads. Required applicants to be licensed medical clinics.
- PICO IV Subscriptions (Subscribe & Save) Recurring subscription program offering 20% savings on repeat orders of PICO IV sterile CBD IV vials for registered clinic and consumer members via the picoiv.com storefront.
Quantifiable outcome
- Available in over 200 clinics across almost all 50 states
- +1 more outcomes
Companies that use Pico IV
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles4 records
Pico IV technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
Feature4 records
Pico IV partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- BrainThrive, PCcoreClinical collaboration to deliver patented sterile CBD solution at BrainThrive's Westlake Village neurology clinic. Creates a neurologist-guided protocol for CBD IV therapy with structured delivery and real-world clinical measurement using AdvancedMD to document patient-reported outcomes alongside neurological indicators. Aligned with December 19 Executive Order on medical marijuana and CBD research priorities.
- The DRIPBaRcoreStrategic partnership to expand access to sterile CBD solutions nationwide through DRIPBaR's franchise locations. The partnership aims to improve wellness support through IV therapy and CBD products, leveraging both companies' reputations and safety standards. Products accessible via franchise's more than 120 locations.
- LiquividacorePartnership to bring first sterile CBD emulsion to mainstream wellness protocols. Liquivida founder Sam Tejada joins PICO IV's Advisory Board as official spokesperson while continuing as Chairman of Leadership Advisory Board for American IV Association. Companies plan to educate providers and patients on endocannabinoid system and integrate pharmaceutical-grade CBD (manufactured in cGMP facility using e-beam sterilization) into customized wellness and performance protocols.
- iCRYOcorePartnership to accelerate availability of CBD IV infusions through iCRYO's national wellness provider network. Pico IV's first-of-its-kind CBD IV therapy (launched August 2023) made available through iCRYO's 50 franchise locations across US and Canada, aiming to accelerate CBD acceptance into mainstream wellness services.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Pico IV competitors and assessment
Company assessmentDirect peers
- Medterra: CBD brand focused on tinctures, capsules, topicals, and sleep/recovery products, including partnerships with healthcare professionals. Comparable positioning as a science-forward, professionally distributed CBD brand targeting practitioner channels.
- CBDistillery: Large-scale CBD brand under Balanced Health Botanicals offering tinctures, gummies, capsules, and topicals with strong value positioning. Comparable as a high-volume CBD brand competing for the same practitioner and consumer audience.
- Elixinol: Global CBD brand (formerly Elixinol Global) producing tinctures, capsules, topicals, and skincare. Comparable as a science-positioned CBD consumer brand with international distribution ambitions.
- Receptra Naturals: CBD brand focused on recovery, sleep, and active-lifestyle SKUs, with professional/athlete channels. Comparable as a specialty CBD brand targeting wellness, recovery, and practitioner-oriented distribution.
- cbdMD: Public CBD brand selling tinctures, gummies, topicals, and sleep/recovery products with national retail and DTC reach. Comparable as a multi-format, mass-distributed CBD brand competing for the same wellness-conscious consumer.
- Lazarus Naturals: Vertically integrated CBD brand offering tinctures, capsules, topicals, and pet products with a strong value and accessibility positioning. Comparable as a multi-format CBD consumer brand with significant scale and broad distribution.
- Restore Hyper Wellness: National franchise chain offering IV therapy, cryotherapy, infrared, and wellness services — closely matching Pico IV's IV therapy clinic channel. Comparable as a distributed IV therapy operator that could similarly partner with or compete for sterile CBD IV suppliers.
Emerging players
- Trokie: Smaller CBD pharma-adjacent brand focused on buccal/sublingual CBD delivery with a clinical/pharmacy distribution angle. Comparable as an emerging, clinically-positioned CBD player with a differentiated delivery format similar in spirit to Pico IV's novel IV route.
Broad incumbents
- Charlotte's Web Holdings: One of the largest and most established CBD wellness brands in the US, selling tinctures, gummies, capsules, and topicals across retail and DTC channels. Comparable as a premium CBD consumer brand, though it lacks Pico IV's sterile IV formulation and B2B clinic channel.
- CV Sciences (PlusCBD Oil): Public CBD company (PlusCBD Oil brand) producing CBD extracts, capsules, topicals, and pet products. Comparable as a regulated, quality-focused CBD manufacturer operating in similar wellness and practitioner channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Pico IV social profiles
Digital presencePico IV compliance and trust
Trust signalCompliance2 records
Pico IV financial estimates
Financial estimateRevenue estimate
Valuation estimate
Pico IV leadership team
Management profileNumber of profiles
Pico IV funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Pico IV M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Pico IV
What does Pico IV do?
Pico IV develops, manufactures, and distributes the world's first sterile CBD IV solution using proprietary pico-emulsion technology that reduces CBD particles to picometer scale (1000x smaller than nanoemulsions), enabling water solubility and passage through sterile filtration for true IV-administerable CBD. The company sells sterile CBD Broad Spectrum Vials (in 5ml, 10ml, 20ml, and 50ml sizes) and a Core-A acidic cannabinoid formulation to licensed medical clinics, wellness franchises, and consumers through a HIPAA-compliant B2B Provider Portal and DTC e-commerce.
Is Pico IV a public or private company?
Pico IV is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Pico IV founded?
Pico IV was founded in 2023. It employs 11 to 50 people.
Where is Pico IV based?
Pico IV is headquartered in Sacramento, United States, in the North America region.
How does Pico IV make money?
Two revenue lines are on record. Sterile CBD IV Product Sales are the primary driver. The others are B2B Provider Portal.
Who are Pico IV's main competitors?
Direct peers on record are Medterra, CBDistillery, Elixinol, Receptra Naturals, cbdMD, Lazarus Naturals and Restore Hyper Wellness. Trokie is listed as an emerging player. Broad incumbents are Charlotte's Web Holdings and CV Sciences (PlusCBD Oil).
Does Pico IV have an API?
No public API is recorded for Pico IV.
What industry is Pico IV in?
Pico IV's product category is Sterile CBD IV Pharmaceutical Products. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of CRAOAIAG, Hemp & CBD Product Wholesale Distribution. Its NAICS code is 325412 and its SIC code is 2834.